CD151-α3β1 integrin complexes suppress ovarian tumor growth by repressing slug-mediated EMT and canonical Wnt signaling

Oncotarget

Volumn 5, Issue 23, 2014, Pages 12203-12217

  Baldwin, Lauren A ^a,b   Hoff, John T ^a,b   Lefringhouse, Jason ^a,b   Zhang, Michael ^a   Jia, Changhe ^a   Liu, Zeyi ^a   Erfani, Sonia ^a   Jin, Hongyan ^a   Xu, Mei ^a   She, Qing Bai ^a   van Nagell, John R ^b   Wang, Chi ^a   Chen, Li ^a   Plattner, Rina ^a   Kaetzel, David M ^c   Luo, Jia ^a   Lu, Michael ^d   West, Dava ^b   Liu, Chunming ^a   Ueland, Fred R ^b   Drapkin, Ronny ^e   Zhou, Binhua P ^a   Yang, Xiuwei H ^a   more..

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d FLORIDA ATLANTIC UNIVERSITY   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

CD151 integrin EMT tumor growth ovarian cancer

Indexed keywords

AXIN; AXIN 2; BETA CATENIN; CD151 ANTIGEN; FIBRONECTIN; MUCIN 5AC; TRANSCRIPTION FACTOR SLUG; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VERY LATE ACTIVATION ANTIGEN 3; CD151 PROTEIN, HUMAN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR; TRANSCRIPTOME; WNT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ARTICLE; ASCITES; CELL ACTIVATION; CELL INTERACTION; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TISSUE MICROARRAY; WNT SIGNALING PATHWAY; ANIMAL; CYSTADENOCARCINOMA; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; XENOGRAFT; ADULT; AGED; ANIMAL TISSUE; APOPTOSIS; CANCER INHIBITION; CELL ADHESION; CELL CONTACT; CELL INVASION; CELL MOTILITY; GENE SILENCING; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; METASTASIS; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD151; CELL LINE, TUMOR; CELL PROLIFERATION; CYSTADENOCARCINOMA, SEROUS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HETEROGRAFTS; HUMANS; INTEGRIN ALPHA3BETA1; MICE; MICE, NUDE; OVARIAN NEOPLASMS; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TRANSCRIPTOME; WNT SIGNALING PATHWAY;

EID: 84920000944     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2622     Document Type: Article

References (65)

1. Lengyel E. Ovarian cancer development and metastasis. The American journal of pathology. 2010; 177(3):1053-1064.
2. Vaughan S, Coward JI, Bast RC, Jr., Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature reviews Cancer. 2011; 11(10):719-725.
3. Landen CN, Jr., Birrer MJ and Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(6):995-1005.
4. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-615.
5. Hiss D. Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. Journal of oncology. 2012; 2012:737981.
6. Saad AF, Hu W and Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer. Hormones & cancer. 2010; 1(6):277-290.
7. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD and Lengyel E. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008; 68(7):2329-2339.
8. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K and Lengyel E. Ligand-independent activation of c-Met by fibronectin and alpha(5)beta(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011; 30(13):1566-1576.
9. Kurrey NK, K A and Bapat SA. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecologic oncology. 2005; 97(1):155-165.
10. Davidson B, Trope CG and Reich R. Epithelialmesenchymal transition in ovarian carcinoma. Frontiers in oncology. 2012; 2:33.
11. Choi YP, Kim BG, Gao MQ, Kang S and Cho NH. Targeting ILK and beta4 integrin abrogates the invasive potential of ovarian cancer. Biochemical and biophysical research communications. 2012; 427(3):642-648.
12. Johnson JL, Winterwood N, DeMali KA and Stipp CS. Tetraspanin CD151 regulates RhoA activation and the dynamic stability of carcinoma cell-cell contacts. J Cell Sci. 2009; 122(Pt 13):2263-2273.
13. Zhang F, Michaelson JE, Moshiach S, Sachs N, Zhao W, Sun Y, Sonnenberg A, Lahti JM, Huang H and Zhang XA. Tetraspanin CD151 maintains vascular stability by balancing the forces of cell adhesion and cytoskeletal tension. Blood. 2011; 118(15):4274-4284.
14. Gourley C, Paige AJ, Taylor KJ, Ward C, Kuske B, Zhang J, Sun M, Janczar S, Harrison DJ, Muir M, Smyth JF and Gabra H. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res. 2009; 69(11):4835-4842.
15. Suzuki N, Higashiguchi A, Hasegawa Y, Matsumoto H, Oie S, Orikawa K, Ezawa S, Susumu N, Miyashita K and Aoki D. Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells. Human cell. 2005; 18(3):147-155.
16. Kazarov AR, Yang X, Stipp CS, Sehgal B and Hemler ME. An extracellular site on tetraspanin CD151 determines alpha 3 and alpha 6 integrin-dependent cellular morphology. Journal of Cell Biology. 2002; 158(7):1299-1309.
17. Chattopadhyay N, Wang Z, Ashman LK, Brady-Kalnay SM and Kreidberg JA. alpha3beta1 integrin-CD151, a component of the cadherin-catenin complex, regulates PTPmu expression and cell-cell adhesion. Journal of Cell Biology. 2003; 163(6):1351-1362.
18. Deng X, Li Q, Hoff J, Novak M, Yang H, Jin H, Erfani SF, Sharma C, Zhou P, Rabinovitz I, Sonnenberg A, Yi Y, Stipp CS, Kaetzel DM, Hemler ME and Yang XH. Integrin-Associated CD151 Drives ErbB2-Evoked Mammary Tumor Onset and Metastasis. Neoplasia. 2012; 14(8):678-689.
19. Yang XWH, Richardson AL, Torres-Arzayus MI, Zhou PC, Sharma C, Kazarov AR, Andzelm MM, Strominger JL, Brown M and Hemler ME. CD151 accelerates breast cancer by regulating alpha(6) integrin function, signaling, and molecular organization. Cancer Res. 2008; 68(9):3204-3213.
20. Mosig RA, Lin L, Senturk E, Shah H, Huang F, Schlosshauer P, Cohen S, Fruscio R, Marchini S, D'Incalci M, Sachidanandam R, Dottino P and Martignetti JA. Application of RNA-Seq transcriptome analysis: CD151 is an Invasion/Migration target in all stages of epithelial ovarian cancer. Journal of ovarian research. 2012; 5:4.
21. Vang R, Shih Ie M and Kurman RJ. Ovarian lowgrade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Advances in anatomic pathology. 2009; 16(5):267-282.
22. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C and Schultz N. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer discovery. 2012; 2(5):401-404.
23. Hashida H, Takabayashi A, Tokuhara T, Hattori N, Taki T, Hasegawa H, Satoh S, Kobayashi N, Yamaoka Y and Miyake M. Clinical significance of transmembrane 4 superfamily in colon cancer. British journal of cancer. 2003; 89(1):158-167.
24. Gesierich S, Paret C, Hildebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, Horejsi V, Yoshie O, Herlyn D, Ashman LK and Zoller M. Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clinical Cancer Research. 2005; 11(8):2840-2852.
25. Winterwood NE, Varzavand A, Meland MN, Ashman LK and Stipp CS. A critical role for tetraspanin CD151 in alpha3beta1 and alpha6beta4 integrin-dependent tumor cell functions on laminin-5. Molecular biology of the cell. 2006; 17(6):2707-2721.
26. Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE and Hemler ME. Disruption of laminin-integrin-CD151-focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res. 2010; 70(6):2256-2263.
27. Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I and Salzet M. Epithelial-mesenchymal transition in ovarian cancer. Cancer letters. 2010; 291(1):59-66.
28. Hemler ME. Tetraspanin functions and associated microdomains. Nature Reviews Molecular Cell Biology. 2005; 6(10):801-811.
29. Hemler ME. Tetraspanin proteins promote multiple cancer stages. Nature reviews Cancer. 2014; 14(1):49-60.
30. Huang YH, Bao Y, Peng W, Goldberg M, Love K, Bumcrot DA, Cole G, Langer R, Anderson DG and Sawicki JA. Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(9):3426-3430.
31. Furuya M, Kato H, Nishimura N, Ishiwata I, Ikeda H, Ito R, Yoshiki T and Ishikura H. Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination: morphologic alteration and reduced expression of beta1 integrin subsets. Cancer Res. 2005; 65(7):2617-2625.
32. Han L, Pansare V, Al-Abbadi M, Husain M and Feng J. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. Diagnostic cytopathology. 2010; 38(5):333-336.
33. Nassour M, Idoux-Gillet Y, Selmi A, Come C, Faraldo ML, Deugnier MA and Savagner P. Slug controls stem/ progenitor cell growth dynamics during mammary gland morphogenesis. PloS one. 2012; 7(12):e53498.
34. Wu ZQ, Li XY, Hu CY, Ford M, Kleer CG and Weiss SJ. Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(41):16654-16659.
35. Liu YN, Abou-Kheir W, Yin JJ, Fang L, Hynes P, Casey O, Hu D, Wan Y, Seng V, Sheppard-Tillman H, Martin P and Kelly K. Critical and reciprocal regulation of KLF4 and SLUG in transforming growth factor beta-initiated prostate cancer epithelial-mesenchymal transition. Molecular and cellular biology. 2012; 32(5):941-953.
36. Hao HX, Xie Y, Zhang Y, Charlat O, Oster E, Avello M, Lei H, Mickanin C, Liu D, Ruffner H, Mao X, Ma Q, Zamponi R, Bouwmeester T, Finan PM, Kirschner MW, et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature. 2012; 485(7397):195-200.
37. Jiang X, Hao HX, Growney JD, Woolfenden S, Bottiglio C, Ng N, Lu B, Hsieh MH, Bagdasarian L, Meyer R, Smith TR, Avello M, Charlat O, Xie Y, Porter JA, Pan S, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(31):12649-12654.
38. Birkenkamp-Demtroder K, Maghnouj A, Mansilla F, Thorsen K, Andersen CL, Oster B, Hahn S and Orntoft TF. Repression of KIAA1199 attenuates Wnt-signalling and decreases the proliferation of colon cancer cells. British journal of cancer. 2011; 105(4):552-561.
39. Takahashi-Yanaga F and Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16(12):3153-3162.
40. Voss MA, Gordon N, Maloney S, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, Wei W, Berditchevski F and Sundar S. Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer. British journal of cancer. 2011; 104(10):1611-1618.
41. Chien CW, Lin SC, Lai YY, Lin BW, Lee JC and Tsai SJ. Regulation of CD151 by hypoxia controls cell adhesion and metastasis in colorectal cancer. Clinical Cancer Research. 2008; 14(24):8043-8051.
42. Owens DM and Watt FM. Influence of beta1 integrins on epidermal squamous cell carcinoma formation in a transgenic mouse model: alpha3beta1, but not alpha2beta1, suppresses malignant conversion. Cancer Res. 2001; 61(13):5248-5254.
43. Sachs N, Secades P, van Hulst L, Kreft M, Song JY and Sonnenberg A. Loss of integrin alpha3 prevents skin tumor formation by promoting epidermal turnover and depletion of slow-cycling cells. Proceedings of the National Academy of Sciences of the United States of America. 2012.
44. Mitchell K, Svenson KB, Longmate WM, Gkirtzimanaki K, Sadej R, Wang X, Zhao J, Eliopoulos AG, Berditchevski F and Dipersio CM. Suppression of integrin alpha3beta1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and crosstalk to endothelial cells. Cancer Res. 2010; 70(15):6359-6367.
45. Ang J, Lijovic M, Ashman LK, Kan K and Frauman AG. CD151 protein expression predicts the clinical outcome of low-grade primary prostate cancer better than histologic grading: a new prognostic indicator? Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2004; 13(11 Pt1):1717-1721.
46. Raymond K, Kreft M, Song JY, Janssen H and Sonnenberg A. Dual Role of alpha6beta4 integrin in epidermal tumor growth: tumor-suppressive versus tumor-promoting function. Molecular biology of the cell. 2007; 18(11):4210-4221.
47. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S, et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 2010; 466(7308):869-873.
48. Kenny HA, Kaur S, Coussens LM and Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. The Journal of clinical investigation. 2008; 118(4):1367-1379.
49. Gu JG, Sumida Y, Sanzen N and Sekiguchi K. Laminin-10/11 and fibronectin differentially regulate integrin-dependent rho and rac activation via p130(Cas)-CrkII-DOCK180 pathway. Journal of Biological Chemistry. 2001; 276(29):27090-27097.
50. Guo W, Keckesova Z, Donaher JL, Shibue T, Tischler V, Reinhardt F, Itzkovitz S, Noske A, Zurrer-Hardi U, Bell G, Tam WL, Mani SA, van Oudenaarden A and Weinberg RA. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell. 2012; 148(5):1015-1028.
51. Dhasarathy A, Phadke D, Mav D, Shah RR and Wade PA. The transcription factors Snail and Slug activate the transforming growth factor-beta signaling pathway in breast cancer. PloS one. 2011; 6(10):e26514.
52. Yang D, Sun Y, Hu L, Zheng H, Ji P, Pecot CV, Zhao Y, Reynolds S, Cheng H, Rupaimoole R, Cogdell D, Nykter M, Broaddus R, Rodriguez-Aguayo C, Lopez-Berestein G, Liu J, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer cell. 2013; 23(2):186-199.
53. Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R and Davidson B. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer. 2005; 103(8):1631-1643.
54. Haslehurst AM, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, Davey S, Squire J, Park PC and Feilotter H. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC cancer. 2012; 12:91.
55. Huang CL, Liu D, Masuya D, Kameyama K, Nakashima T, Yokomise H, Ueno M and Miyake M. MRP-1/CD9 gene transduction downregulates Wnt signal pathways. Oncogene. 2004; 23(45):7475-7483.
56. Chairoungdua A, Smith DL, Pochard P, Hull M and Caplan MJ. Exosome release of beta-catenin: a novel mechanism that antagonizes Wnt signaling. J Cell Biol. 2010; 190(6):1079-1091.
57. Tsujino K, Takeda Y, Arai T, Shintani Y, Inagaki R, Saiga H, Iwasaki T, Tetsumoto S, Jin Y, Ihara S, Minami T, Suzuki M, Nagatomo I, Inoue K, Kida H, Kijima T, et al. Tetraspanin CD151 Protects against Pulmonary Fibrosis by Maintaining Epithelial Integrity. American journal of respiratory and critical care medicine. 2012.
58. Koo BK, Spit M, Jordens I, Low TY, Stange DE, van de Wetering M, van Es JH, Mohammed S, Heck AJ, Maurice MM and Clevers H. Tumour suppressor RNF43 is a stemcell E3 ligase that induces endocytosis of Wnt receptors. Nature. 2012; 488(7413):665-669.
59. Kovalenko OV, Yang XH and Hemler ME. A novel cysteine cross-linking method reveals a direct association between claudin-1 and tetraspanin CD9. Molecular & Cellular Proteomics. 2007; 6(11):1855-1867.
60. Houle CD, Ding XY, Foley JF, Afshari CA, Barrett JC and Davis BJ. Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. Gynecologic oncology. 2002; 86(1):69-78.
61. Shang X, Lin X, Alvarez E, Manorek G and Howell SB. Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases. Neoplasia. 2012; 14(10):974-985.
62. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J and Bast RC, Jr. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic oncology. 2005; 99(2):267-277.
63. Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC, Jr. and Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation. 2008; 76(10):1081-1092.
64. Jin H, Yu Y, Zhang T, Zhou X, Zhou J, Jia L, Wu Y, Zhou BP and Feng Y. Snail is critical for tumor growth and metastasis of ovarian carcinoma. International journal of cancer Journal international du cancer. 2010; 126(9):2102-2111.
65. Yang XW, Claas C, Kraeft SK, Chen LB, Wang ZM, Kreidberg JA and Hemler ME. Palmitoylation of tetraspanin proteins: Modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology. Molecular biology of the cell. 2002; 13(3):767-781.